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Background
Amyloid beta (Ab) aggregation is well studied as a
major marker and determinant of Alzheimer’s disease
(AD) pathology. While less work has been carried out
on the role of energy metabolism in AD, there is good
evidence that it also contributes to the disease. For exam-
ple, low metabolic rate and ATP levels are also correlated
with AD, which also extends to specific enzymes, meta-
bolites, and proteins associated with glycolysis and the
TCA cycle. Dihydrolipoamide dehydrogenase (DLD-1),
the subject of this study, is a core metabolic enzyme with
specific sequence variants that are associated with
increased risk of late onset AD. DLD-1 contributes to
four major metabolic multi-enzyme complexes, including
a-ketoglutarate dehydrogenase (KGDH). A non-DLD
subunit of KGDH also has variants that are associated
with AD. Additionally, the activity level of the enzyme is
significantly inversely correlated with the disease state in
humans.
Materials and methods
We used a previously published C. elegans model of AD
that consists of two strains CL2006 and CL4176, which
produce human amyloid beta (1-42) in body-wall muscle
cells either constitutively or by temperature upshift,
respectively. Ab aggregation results in muscle impair-
ment, observed as paralysis, which is particularly appar-
ent when a muscle stimulant is applied. Using this
assay, we chemically or genetically modified the function
or abundance of DLD-1, to determine whether this
could modify disease progression or remission. We also
modified other metabolic functions to see whether the
observed effect was specific to DLD.
Results
Expression of human Ab caused significant paralysis of C.
elegans in the presence of each of the stimulants, aldicarb
and serotonin (5-HT). This effect was completely
reversed when the dld-1 gene was suppressed in either
the constitutive or the inducible Ab producing strain.
The same effect was observed with chemicals that inhi-
bited metabolic pathways involving DLD-1, but not with
an uncoupler of the mitochondrial electron transport
chain that depletes ATP production capacity. Thus, it
was not energy depletion, per se, that caused the effect.
Rather, the critical factor seems to be inhibition of an, as
yet loosely defined, DLD-1 containing metabolic path-
way. The chemicals that were effective in alleviating the
Ab mediated pathology in the model also decreased Ab
aggregation. Interestingly, one of the chemicals in parti-
cular effectively decreased Ab aggregation and reduced
the behavioural pathology regardless of whether the Ab
was pre-expressed or co-expressed with the chemical
treatment.
Conclusions
Our results show that inhibition of DLD-1 in our model
has protective effects against Ab toxicity although the
precise mechanism is not yet fully understood.
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